- Home
- SISI vs CATX Comparison
SISI vs CATX Comparison
Compare SISI & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- CATX
- Stock Information
- Founded
- SISI 1997
- CATX 1983
- Country
- SISI China
- CATX United States
- Employees
- SISI N/A
- CATX N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- CATX Medical/Dental Instruments
- Sector
- SISI Health Care
- CATX Health Care
- Exchange
- SISI Nasdaq
- CATX Nasdaq
- Market Cap
- SISI 227.4M
- CATX 239.0M
- IPO Year
- SISI 2016
- CATX N/A
- Fundamental
- Price
- SISI $7.78
- CATX $3.38
- Analyst Decision
- SISI
- CATX Strong Buy
- Analyst Count
- SISI 0
- CATX 11
- Target Price
- SISI N/A
- CATX $12.90
- AVG Volume (30 Days)
- SISI 1.6M
- CATX 641.6K
- Earning Date
- SISI 11-13-2025
- CATX 11-11-2025
- Dividend Yield
- SISI N/A
- CATX N/A
- EPS Growth
- SISI N/A
- CATX N/A
- EPS
- SISI N/A
- CATX N/A
- Revenue
- SISI $9,601,324.00
- CATX $1,235,000.00
- Revenue This Year
- SISI N/A
- CATX N/A
- Revenue Next Year
- SISI N/A
- CATX N/A
- P/E Ratio
- SISI N/A
- CATX N/A
- Revenue Growth
- SISI 1133.26
- CATX N/A
- 52 Week Low
- SISI $4.71
- CATX $1.60
- 52 Week High
- SISI $664.80
- CATX $15.28
- Technical
- Relative Strength Index (RSI)
- SISI 59.66
- CATX 50.68
- Support Level
- SISI $5.02
- CATX N/A
- Resistance Level
- SISI $6.80
- CATX $3.49
- Average True Range (ATR)
- SISI 0.59
- CATX 0.21
- MACD
- SISI 0.36
- CATX -0.12
- Stochastic Oscillator
- SISI 90.61
- CATX 87.92
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.